Why the study?
Does the EV71 vaccine prevent EV71-associated hand, foot, and mouth disease or herpangina in infants and young children?
Does the EV71 vaccine prevent EV71-associated hand, foot, and mouth disease or herpangina in infants and young children?
The EV71 vaccine is effective in protecting infants and young children against EV71-associated hand, foot, and mouth disease or herpangina.
Supports EV71 vaccination in infants and young children; confirms RCT efficacy against associated disease.
The EV71 vaccine provided protection against EV71-associated hand, foot, and mouth disease or herpangina in infants and young children. (Funded by Sinovac Biotech; ClinicalTrials.gov number, NCT01507857.).
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: